Responses
EULAR 2014: Scientific Abstracts
Poster Presentations. Spondyloarthritis - treatment
SAT0351 Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 96-Week Outcomes of the Rapid-Axspa Trial
Compose a Response to This Article
Other responses
No responses have been published for this article.